Deep learning classification of drug-related problems from pharmaceutical interventions issued by hospital clinical pharmacists during medication prescription review: a large-scale descriptive retrospective study in a French university hospital.

OBJECTIVES: Pharmaceutical interventions are proposals made by hospital clinical pharmacists to address sub-optimal uses of medications during prescription review. Pharmaceutical interventions include the identification of drug-related problems, their prevention and resolution. The objective of this study was to exploit a newly developed deep neural network classifier to identify drug-related problems from pharmaceutical interventions and perform a large retrospective descriptive analysis of them in a French university hospital over a 3-year period.

METHODS: Data were collected from prescription support software from 2018 to 2020. A classifier running in Python 3.8 and using Keras library was then used to automatically categorise drug-related problems from pharmaceutical interventions according to the coding of the French Society of Clinical Pharmacy.

RESULTS: 2 930 656 prescription lines were analysed for a total of 119 689 patients. Among these prescription lines, 153 335 (5.2%) resulted in pharmaceutical interventions (n=48 202 patients; 40.2%). Pharmaceutical interventions were predominantly observed in patients aged 65 years or older (n=26 141 patients out of 53 186; 49.1%) and in patients taking five or more medications (44 702 patients out of 93 419; 47.8%). The most frequently identified types of drug-related problems associated with pharmaceutical interventions were 'Non-conformity to guidelines or contra-indication' (n=88 523; 57.7%), 'Overdosage' (16 975; 11.1%) and 'Improper administration' (13 898; 9.1%). The most frequently encountered drugs were: paracetamol (n=10 585; 6.9%), esomeprazole (6031; 3.9%), hydrochlorothiazide (2951; 1.9%), enoxaparin (2191; 1.4%), tramadol (1879; 1.2%), calcium (2073; 1.3%), perindopril (1950; 1.2%), amlodipine (1716; 1.1%), simvastatin (1560; 1.0%) and insulin (1019; 0.7%).

CONCLUSIONS: The deep neural network classifier used met the challenge of automatically classifying drug-related problems from pharmaceutical interventions from a large database without mobilising significant human resources. The use of such a classifier can lead to alerting caregivers about certain risky practices in prescription and administration, and triggering actions to improve patients' therapeutic outcomes.